نتایج جستجو برای: Peptide Receptor Radionuclide Therapy

تعداد نتایج: 1363778  

Journal: :Annals of the New York Academy of Sciences 2004

Objective(s): Somatostatin receptor-positive neuroendocrine tumors have been targeted using various peptide analogs radiolabeled with therapeutic radionuclides for years. The better biomedical properties of radioantagonists as higher tumor uptake make these radioligands more attractive than agonists for somatostatin receptor-targeted radionuclide therapy. In this study...

Journal: :Annals of the New York Academy of Sciences 2004
Eric P Krenning Dik J Kwekkeboom Roelf Valkema Stanislas Pauwels Larry K Kvols Marion De Jong

On their plasma membranes, cells express receptor proteins with high affinity for regulatory peptides, such as somatostatin. Changes in the density of these receptors during disease, for example, overexpression in many tumors, provide the basis for new imaging methods. The first peptide analogues successfully applied for visualization of receptor-positive tumors were radiolabeled somatostatin a...

Journal: :Journal of Nuclear Medicine Technology 2018

Journal: :Clinical Oncology 2021

Peptide receptor radionuclide therapy is a type of molecular radiotherapy that has been used in the treatment patients with neuroendocrine tumours for over two decades. It not until recently, however, it achieved regulatory approval. The currently approved regimen one-size-fits-all scheme, i.e. all receive fixed activity radiopharmaceutical (177Lu-DOTATATE) and number cycles. Several research g...

We present the case of a 60-year-old man with metastatic neuroendocrine tumor of the ileum following ileal resection, being evaluated for 177Lu-based peptide receptor radionuclide therapy. 68Ga-DOTANOC PET/CT showed focal increased tracer uptake in the scrotal region without any morphologic changes on the corresponding CT images. Similar increased tracer uptake was seen on...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید